By Liz Moyer
Investing.com -- Gilead (NASDAQ:GILD) reported third quarter earnings and revenue that were lower than last year but topped expectations and it raised its guidance for the full year.
The pharmaceutical company reported earnings per share of $1.90 on revenue of $7 billion. Analysts polled by Investing.com anticipated EPS of $1.52 on revenue of $6.13 billion.
Gilead shares jumped 2.5% in after-hours trading. They are down 3% from the beginning of the year, and 5.29% from its 52-week high of $74.12 set on Dec. 30, 2021.
The total third quarter revenue was down 5% from last year because of lower sales of its Covid anti-viral treatment remdesivir, partially offset by increased sales in HIV and oncology products. Sales of Biktarvy, its HIV treatment, rose 22%. Profit was down 28%.
It raised its full year outlook for total product sales to between $25.9 billion and $26.2 billion, compared with previous guidance for $24.5 billion and $25.0 billion. It also forecasts full year adjusted earnings per share between $6.95 and $7.15, compared with $6.35 and $6.75. Full year earnings per share are forecast to be between $3.35 and $3.55, compared to $2.90 and $3.30 previously.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.